Leveraging Fully Integrated Solutions to Support Your Glp-1 Developments

The GLP-1 receptor agonist market is rapidly expanding, driven by the increasing prevalence of obesity and the emergence of new therapeutic indications. As the competition intensifies, GLP1 drug developers are facing the complexity of developing new drug combinations, securing their supply chain and ensuring their solutions to promote patient adherence. In this presentation Aptar Pharma will examine GLP-1 development hurdles and discuss how Pharma Companies can leverage our expertise in components manufacturing, drug development and patient services as well as digital solutions, from Formulation to Patient.